← Back to Search

Transcranial Magnetic Stimulation

Accelerated Theta-Burst Stimulation for Obsessive-Compulsive Disorder

Stanford, CA
N/A
Recruiting
Led By Nolan Williams, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Capacity to provide informed consent
Meets Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for OCD with a moderate level of severity as defined by a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 18
Must not have
Age of OCD symptom onset >30
History of receiving Electroconvulsive Therapy (ECT) (assessed during baseline by study MD)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (pretreatment) to immediate post-treatment follow up
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if an accelerated schedule of theta-burst stimulation using a TMS device can help people with OCD who haven't responded to other treatments.

See full description
Who is the study for?
This trial is for adults with moderate to severe OCD who haven't responded well to standard treatments like SRIs or cognitive behavioral therapy. Participants must be stable on SRI medication for at least 8 weeks and able to undergo study procedures. Excluded are those with substance abuse issues, severe depression, bipolar disorder, eating disorders, certain medical conditions like seizures or brain injuries, pregnant or nursing women, and anyone planning CBT during the study.Check my eligibility
What is being tested?
The trial tests an accelerated form of Transcranial Magnetic Stimulation (TMS) called theta-burst stimulation in two different brain areas: the dorsomedial prefrontal cortex (DMPFC) and the right orbitofrontal cortex (rOFC). Participants will be randomly assigned to receive treatment at one of these sites.See study design
What are the potential side effects?
Potential side effects from TMS may include discomfort at the stimulation site, headache, lightheadedness, tingling or spasms in facial muscles. Rarely it can cause seizures. Most side effects are mild and temporary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand and can agree to the study's procedures and risks.
 show original
Select...
I have been diagnosed with OCD and it's moderately severe.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My OCD symptoms started after I turned 30.
 show original
Select...
I have undergone Electroconvulsive Therapy.
 show original
Select...
I have had an implanted device or psychosurgery.
 show original
Select...
I have a history of brain-related health issues or a close relative with seizures.
 show original
Select...
My depression is not severe based on my last HDRS-17 score.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pretreatment) to immediate post-treatment follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pretreatment) to immediate post-treatment follow up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage change in Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Secondary study objectives
Percent change in the Obsessive-Compulsive Inventory-Revised (OCI-R)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: right OFCActive Control1 Intervention
This arm will receive continuous theta-burst stimulation to the right OFC site.
Group II: bilateral DMPFCActive Control1 Intervention
This arm will receive intermittent theta-burst stimulation to bilateral DMPFC site.

Find a Location

Closest Location:Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine· Stanford, CA· 2105 miles

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,525 Previous Clinical Trials
17,427,939 Total Patients Enrolled
16 Trials studying Obsessive-Compulsive Disorder
1,230 Patients Enrolled for Obsessive-Compulsive Disorder
Nolan Williams, MDPrincipal InvestigatorStanford University
17 Previous Clinical Trials
981 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
367 Patients Enrolled for Obsessive-Compulsive Disorder
Ian Kratter, MD, PhDPrincipal InvestigatorStanford University
2 Previous Clinical Trials
67 Total Patients Enrolled

Media Library

Active bilateral DMPFC (Transcranial Magnetic Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04286126 — N/A
Obsessive-Compulsive Disorder Research Study Groups: right OFC, bilateral DMPFC
Obsessive-Compulsive Disorder Clinical Trial 2023: Active bilateral DMPFC Highlights & Side Effects. Trial Name: NCT04286126 — N/A
Active bilateral DMPFC (Transcranial Magnetic Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04286126 — N/A
Obsessive-Compulsive Disorder Patient Testimony for trial: Trial Name: NCT04286126 — N/A
~10 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top